18 / 25
Page 46
allied
academies
February 25-26, 2019 | Paris, France
13
th
World Cancer Congress
Journal of Medical Oncology and Therapeutics | Volume 4
Notes:
Neoadjuvant Chemo-Radio Therapy in carcinoma esophagus- HCG Ahmedabad experience
Samir Batham
HCG Cancer, India
C
ancer of the esophagus is the eighth most common cancer
worldwide. Most of the patients present in moderate to
locally advanced stage, where outcomes following surgery
alone are not very promising. The role of neoadjuvant
chemo radiotherapy was quite controversial till few years
back. The Cross group in August 2015 established the role of
neoadjuvant chemoradiotherapy in esophageal and gastro
oesohageal cancers, with better survival outcomes and
acceptable toxicities. In India neoadjuvant chemoradiotherapy
for esophageal cancers is still not widely practiced. We at our
center are utilizing this strategy since 2012. Here I am sharing
our initial experience of neoadjuvant chemoradiotherapy in
cancer of esophagus treated between January 2012 till August
2016. Of the total 87 patients, 77 patients with clinically node
positive disease and a disease segment of more than 2 cm
underwent preoperative chemo radiotherapy. The radiation
dose ranged from 41.4Gy to 50.4Gy. All the patients received
weekly chemotherapy with Paclitaxel and Carboplatin. 36
patients underwent Ivor- Lewis surgery, 45 patients underwent
subtotal esophagectomy, and 6 were inoperable. 61 were
squamous cell carcinoma, 25 were adenocarcinoma and 1 was
sarcoma. 26 patients had pathological complete response and
20 patients had good response, 19 patients showed moderate
response and 12 patients had poor response. Mucositis was
the most common side effect. The results and toxicities were
comparable with the results of Cross trial. The long follow up
will provide the data regarding survival outcomes and late
toxicities in our patients. But as of now the initial experience
has shown promising outcomes of using this strategy.
e:
drsamir2772@gmail.com